Exenatide Dosage: 5 to 10 Micrograms Twice a Day or 2 Milligrams a Week — and Every Original Brand Now Listed as Discontinued

Exenatide, the first GLP-1 drug, has two labelled regimens that differ fourteen-fold in weekly amount: immediate-release twice daily before meals, and extended-release once a week. FDA's database now lists Byetta, Bydureon and Bydureon BCise as discontinued, leaving a 2024 generic of the twice-daily pen. The label figures, the arithmetic between them, timing and missed-dose rules, kidney limits, and the antibody data.

Robert F · Edited by Caroline S · Published 2026-10-03

Illustration: Various empty glass vials, pipettes, and beakers arranged on a cool grey lab bench. — Illustration

Exenatide was the first GLP-1 drug approved in the United States, in 2005. It is also the only one with two labelled regimens that differ more than tenfold in weekly amount — and, as of this month, the only one whose original brands FDA's database lists as discontinued.

The label figures

Product	Application	Dose	Timing
BYETTA (immediate-release)	NDA 021773, approved 2005-04-28 — listed discontinued	5 mcg twice daily; may increase to 10 mcg twice daily after 1 month	Within 60 minutes before morning and evening meals (or two main meals ≥6 h apart); not after a meal
Exenatide injection, Amneal (generic of BYETTA)	ANDA 206697, approved 2024-11-19 — listed prescription	Same as BYETTA	Same as BYETTA
BYDUREON (extended-release, vial/pen)	NDA 022200, approved 2012-01-27 — listed discontinued	2 mg	—
BYDUREON BCISE (extended-release autoinjector)	NDA 209210, approved 2017-10-20 — listed discontinued	2 mg once every 7 days	Any time of day, with or without meals

Marketing status is as Drugs@FDA reported it on 3 October 2026. The BYDUREON BCISE label quoted here is the 2025 revision still held in FDA's label archive; DailyMed no longer carries a BYDUREON listing.

All four are approved only for type 2 diabetes — the immediate-release products for adults, BCISE for adults and children aged 10 and older. Exenatide has no weight-management approval.

Fourteen times as much, once a week

At the top immediate-release dose, the weekly total is simple: 10 mcg × 2 × 7 = 140 mcg. The extended-release dose is 2,000 mcg in one injection — about 14 times as much exenatide a week for the same molecule.

The reason is delivery, not potency. Immediate-release exenatide peaks about 2.1 hours after injection, has a mean terminal half-life of 2.4 hours and is measurable for about 10 hours (BYETTA label) — hence two doses a day timed to meals. The weekly form holds exenatide in extended-release microspheres in an oil-based vehicle; after a single dose the BCISE label describes plasma concentrations peaking at around week 6 to 7, so a much larger amount is needed to keep concentrations up across the week. The switching section of the BCISE label reflects the build-up: people changing from immediate-release exenatide "may experience transient (approximately 2 to 4 weeks) elevations in blood glucose concentrations."

A dose figure for exenatide is therefore meaningless without the formulation. A microgram number from a twice-daily pen and a milligram number from a weekly injection describe two different products.

The pens, in numbers

Both immediate-release pens contain exenatide at 250 mcg/mL and give 60 fixed doses:

Pen	Contents	Per dose	Doses	Discard
5 mcg	300 mcg in 1.2 mL	0.02 mL	60 (30 days at twice daily)	30 days after first use
10 mcg	600 mcg in 2.4 mL	0.04 mL	60 (30 days at twice daily)	30 days after first use

The volumes per dose are our division of the label's contents by its dose count. The pens are fixed-dose devices; the labels give no instruction for drawing exenatide into a syringe. The BCISE autoinjector holds 2 mg in 0.85 mL of suspension. How fixed-dose pens differ from vials is covered on our peptide pen page.

Timing and missed doses

Immediate-release: any time in the 60 minutes before the two main meals, at least six hours apart, never after the meal; a missed dose is skipped and the schedule resumes with the next one.
Weekly: a missed dose is given when noticed if the next scheduled dose is at least three days away; the weekly day can be changed if the last dose was at least three days earlier.

Kidneys, antibodies and the boxed warning

Kidneys. Exenatide is eliminated mainly by glomerular filtration. The immediate-release labels do not recommend it in severe impairment (creatinine clearance below 30 mL/min) or end-stage kidney disease; the BCISE label draws the line higher, at an eGFR of 45.

Antibodies. The immediate-release label reports antibody testing in its 30-week trials: 38% of patients had low-titre antibodies, generally with glucose control comparable to those without; 6% had higher-titre antibodies, and half of those — 3% of all patients — had a weakened glucose response.

Boxed warning. The BCISE label carries a boxed warning for thyroid C-cell tumours, as the weekly GLP-1 drugs do. The immediate-release labels carry no boxed warning. The BCISE label also lists serious injection-site reactions (abscess, cellulitis, necrosis) reported after marketing; injection-site nodules were among its most common reactions (10.5% in its trial table), and injection-site reactions overall occurred in 23.9% of adults in its two 28-week comparator trials.

The side-effect record of GLP-1 drugs as a class is covered in depth by GLP1 Ledger; the label figures for the newer molecules are on our semaglutide, liraglutide and tirzepatide dosage pages.

What is not covered by the labels

No label gives an exenatide dose for weight loss in people without diabetes, for any "research" product, or for exenatide powder reconstituted by the user — research-market vials are not the approved pens and carry none of their testing. No label converts between exenatide doses and those of other GLP-1 drugs. What the molecule is, and its origin in the Gila monster, is in Peptide Lexicon's exenatide entry; this site's other label-based dose pages are indexed on the peptide dosage chart.

Every figure here is reported from the published labels with their dates. None is offered as a dose to use; decisions about any medicine belong with a prescriber.

Sources and dates

BYETTA (exenatide) injection, AstraZeneca, NDA 021773, label effective 2025-09-02 via openFDA: dosage and administration, dosage forms, adverse reactions (immunogenicity), pharmacokinetics, how supplied, read 2026-10-03.
Exenatide Injection USP, Amneal, ANDA 206697, label effective 2026-05-27 via openFDA (DailyMed SPL published 2026-06-30): dosage forms, renal impairment, read 2026-10-03.
BYDUREON BCISE (exenatide extended-release) injectable suspension, AstraZeneca, NDA 209210, label revision 2025 (accessdata.fda.gov 209210s025lbl.pdf): boxed warning, dosage and administration, warnings, adverse reactions, read 2026-10-03.
Drugs@FDA via openFDA: NDA 021773, NDA 022200, NDA 209210, ANDA 206697 — original approval dates and product marketing status, read 2026-10-03.
DailyMed SPL search, "bydureon" (no current listing) and "exenatide", read 2026-10-03.

Corrections go to the contact page.

Peptifact facts

The immediate-release exenatide labels (BYETTA, NDA 021773; Amneal's generic exenatide injection, ANDA 206697) start at 5 mcg subcutaneously twice daily within the 60 minutes before the morning and evening meals, or the two main meals at least 6 hours apart, and allow 10 mcg twice daily after one month based on clinical response. The labels say not to inject after a meal.
The extended-release BYDUREON BCISE label (NDA 209210, revised 2025) gives 2 mg subcutaneously once every 7 days, at any time of day, with or without meals, for adults and children aged 10 and older with type 2 diabetes.
At the top immediate-release dose, 10 mcg twice daily is 140 mcg a week; the weekly extended-release dose is 2,000 mcg — about 14 times as much exenatide per week for the same drug.
Drugs@FDA listed BYETTA (approved 2005-04-28), BYDUREON (2012-01-27) and BYDUREON BCISE (2017-10-20) as discontinued when read on 3 October 2026. The marketed product it listed was Amneal's generic exenatide injection, approved 2024-11-19, with the same two pen strengths as BYETTA.
Both immediate-release pens hold exenatide at 250 mcg/mL: the 5 mcg pen contains 300 mcg in 1.2 mL and the 10 mcg pen 600 mcg in 2.4 mL, each giving 60 fixed doses, and each is discarded 30 days after first use.
The BYETTA label gives a median time to peak concentration of 2.1 hours, a mean terminal half-life of 2.4 hours, and measurable concentrations for about 10 hours after a dose; exenatide is cleared mainly by the kidneys, and the immediate-release labels do not recommend it below a creatinine clearance of 30 mL/min. The BCISE label does not recommend it below an eGFR of 45 mL/min/1.73 m².
In the immediate-release label's 30-week trials, 38% of patients had low-titre antibodies to exenatide and 6% higher-titre antibodies; 3% of all patients had an attenuated glucose response. The weekly product carries a boxed warning for thyroid C-cell tumours; the twice-daily labels carry none.

Frequently asked questions

What is the dose of exenatide?

The labels give two regimens. Immediate-release exenatide (BYETTA and its generic) starts at 5 micrograms injected twice daily within the hour before the morning and evening meals, with 10 micrograms twice daily allowed after a month based on response. Extended-release exenatide (BYDUREON BCISE) is 2 milligrams injected once every seven days. Both are approved for type 2 diabetes only. These are the label figures as published, not a recommendation for anyone.

Why is weekly exenatide so much more than the twice-daily dose?

At the top twice-daily dose a week adds up to 140 micrograms, while the weekly product is 2,000 micrograms — about 14 times as much. The weekly form holds exenatide in microspheres that release it slowly over weeks, so far more drug is needed per week to keep levels up between injections. The BCISE label notes that people switching from the twice-daily form may see glucose rise for about two to four weeks while levels build.

Is Byetta discontinued?

FDA's Drugs@FDA database listed BYETTA, BYDUREON and BYDUREON BCISE as discontinued when read on 3 October 2026. It listed a generic exenatide injection from Amneal, approved in November 2024, as a marketed prescription product, in the same 5 and 10 microgram pen strengths as BYETTA. Availability at any pharmacy is a separate question this record does not answer.

When is exenatide injected in relation to meals?

The immediate-release labels specify any time within the 60 minutes before the morning and evening meals, or before the two main meals of the day at least six hours apart, and say not to administer it after a meal. The weekly BCISE label allows any time of day, with or without meals, and allows the weekly day to change if the previous dose was at least three days earlier.

Can exenatide be used with kidney disease?

The labels set limits because the drug is cleared mainly by the kidneys. The immediate-release labels do not recommend it in severe kidney impairment (creatinine clearance below 30 mL/min) or end-stage kidney disease and advise caution after kidney transplantation. The BCISE label does not recommend it below an eGFR of 45. Kidney function is assessed by the prescriber.

Is exenatide the same as semaglutide or other GLP-1 drugs?

No. Exenatide is a synthetic 39-amino-acid peptide amide that, per its label, was originally identified in the Gila monster (Heloderma suspectum), and it was the first GLP-1 receptor agonist approved in the US (2005). Its half-life of about 2.4 hours is why the original form is injected twice a day, against once weekly for injected semaglutide. Doses in micrograms or milligrams are not comparable between the drugs.